- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL releases cardiac version of HDI 3000
Ultrasound vendor ATL has put the finishing touches on a cardiacversion of its high-end HDI 3000 ultrasound scanner. The systemwill be ATL's premium cardiac offering, positioned above the scannersthe Bothell, WA, firm acquired through its takeover of
Ultrasound vendor ATL has put the finishing touches on a cardiacversion of its high-end HDI 3000 ultrasound scanner. The systemwill be ATL's premium cardiac offering, positioned above the scannersthe Bothell, WA, firm acquired through its takeover of Interspeclast year.
To optimize HDI 3000 for cardiac imaging, ATL added cardiac protocolsto the system's tissue specific imaging (TSI) feature, which providesusers with a series of predetermined settings that optimize thescanner's parameters for the type of exam being conducted. ATLalso refined other cardiac-specific functions on HDI 3000, suchas EKG. The probes required for cardiac imaging are already onthe market.
ATL also has refined its Color Power Angio power Doppler techniquefor cardiac applications. Rather than focus on blood flow andminute vessels as power Doppler techniques do, Power Motion Imagingshows heart wall motion.
In other ATL news, the company said it expects to post resultsfor the second quarter of 1995 that meet analysts' predictionsranging from a loss of 2¢ a share to a profit of 8¢,according to Dow Jones News Service.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
